Nkarta, Inc.

NKTXSEC EDGAR

Pharmaceutical Preparations(DE)CIK: 1787400

Concept	FY2024	FY2023	FY2022	FY2021	FY2020
Revenue from Contract with Customer, Excluding Assessed Tax	$0.00	$0.00	$0.00	$0.00	$115.0K
Research and Development Expense	$96.8M	$90.9M	$63.4M	$36.2M	$17.2M
Operating Expenses	$131.7M	$119.0M	$86.4M	$51.5M	$22.5M
Operating Income (Loss)	-$131.7M	-$119.0M	-$86.4M	-$51.5M	-$22.3M
Nonoperating Income (Expense)	$14.1M	$5.1M	$354.0K	-$39.9M	$1.3M
Income Tax Expense (Benefit)	$0.00	$0.00	$0.00	$0.00	$0.00
Net Income (Loss) Attributable to Parent	-$117.5M	-$113.8M	-$86.1M

Concept	FY2024	FY2023	FY2022	FY2021	FY2020
Assets	$378.9M	$472.9M	$273.9M	$337.6M	$48.4M
Assets, Current	$253.1M	$360.7M	$245.8M	$318.8M	$37.5M
Cash and Cash Equivalents, at Carrying Value	$31.0M	$37.5M	$60.8M	$96.7M	$20.6M
Liabilities	$105.6M	$100.7M	$22.9M	$16.4M	$14.1M
Liabilities, Current	$23.3M	$22.0M	$12.9M	$8.8M	$8.2M
Accounts Payable, Current	$3.7M	$1.8M	$1.1M	$1.2M	$1.9M
Stockholders' Equity Attributable to Parent	$372.2M	$251.0M	$321.2M	-$25.5M

Concept	FY2024	FY2023	FY2022	FY2021	FY2020
Net Cash Provided by (Used in) Operating Activities	-$86.2M	-$57.0M	-$67.9M	-$43.5M	-$18.4M
Net Cash Provided by (Used in) Investing Activities	$79.0M	-$184.7M	$32.5M	-$210.1M	-$18.3M
Net Cash Provided by (Used in) Financing Activities	$691.0K	$219.0M	$1.2M	$329.8M	$49.6M
Payments to Acquire Property, Plant, and Equipment	$28.1M	$47.1M	$5.0M	$7.5M	$1.9M

Access SEC EDGAR data via REST API. Free tier available.

from sec_edgar import SecEdgar

api = SecEdgar("YOUR_KEY")
api.revenue("AAPL", limit=5)